Meeting
2018 ASCO Annual Meeting
A phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor (TKI) naïve patients with advanced NSCLC.
Authors
Aaron Elliott Lisberg
UCLA, Los Angeles, CA
Aaron Elliott Lisberg , Amy Lauren Cummings , Jonathan Wade Goldman , Krikor Bornazyan , Nicholas Dean Reese , Tina Wang , Paul Coluzzi , Blanca A. Ledezma , Melody A. Mendenhall , Benjamin Jones , John Madrigal , James M. Carroll , Jaklin Gukasyan , Tawny Williams , Lauren Sauer , Courtney L Wells , Ariana R Hardy , Paulina J Linares , Carlos R. Adame , Edward B. Garon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT02879994
Citation
J Clin Oncol 36, 2018 (suppl; abstr 9014)
DOI
10.1200/JCO.2018.36.15_suppl.9014
Abstract #
9014
Poster Bd #
337
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
A randomized phase II study comparing nivolumab (NIVO) with carboplatin-pemetrexed (CbPEM) for patients (pts) with EGFR mutation-positive non-small cell lung cancer (NSCLC) who acquire resistance to tyrosine kinase inhibitors (TKIs) not due to a secondary T790M mutation (WJOG8515L).
First Author: Hidetoshi Hayashi
Poster
2023 ASCO Annual Meeting
Phase 2 trial of epidermal growth factor (EGF) vaccine CIMAvax in combination with pembrolizumab in first line and maintenance setting in advanced non–small cell lung cancer patients.
First Author: Prantesh Jain
Poster
2023 ASCO Annual Meeting
ARC-10: A phase 3 study to evaluate zimberelimab + domvanalimab versus pembrolizumab in front-line, PD-L1-high, locally advanced or metastatic non–small-cell lung cancer.
First Author: Christos Chouaid
Poster
2022 ASCO Annual Meeting
Efficacy and safety of capmatinib plus pembrolizumab in treatment (tx)-naïve patients with advanced non–small cell lung cancer (NSCLC) with high tumor PD-L1 expression: Results of a randomized, open-label, multicenter, phase 2 study.
First Author: Tony S. K. Mok